Page last updated: 2024-12-11
kmi-429
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
KMI-429: a protease inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6918785 |
| CHEMBL ID | 183546 |
| SCHEMBL ID | 14341943 |
| MeSH ID | M0483978 |
Synonyms (8)
| Synonym |
|---|
| kmi-429 |
| bdbm50157441 |
| 5-{(s)-3-[2-((s)-2-{(2s,3s)-2-amino-3-[(1h-tetrazole-5-carbonyl)-amino]-propionylamino}-3-methyl-butyrylamino)-4-methyl-pentanoylamino]-2-hydroxy-1-(r)-oxo-4-phenyl-butylamino}-isophthalic acid |
| 5-((2r,3s)-3-((s)-2-((s)-2-((s)-2-amino-3-(2h-tetrazole-5-carboxamido)propanamido)-3-methylbutanamido)-4-methylpentanamido)-2-hydroxy-4-phenylbutanamido)isophthalic acid |
| CHEMBL183546 , |
| 5-[[(2r,3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(2h-tetrazole-5-carbonylamino)propanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-2-hydroxy-4-phenylbutanoyl]amino]benzene-1,3-dicarboxylic acid |
| SCHEMBL14341943 |
| 3-[(2h-tetrazol-5-ylcarbonyl)amino]-l-alanyl-l-valyl-n-((1s,2r)-1-benzyl-3-[(3,5-dicarboxyphenyl)amino]-2-hydroxy-3-oxopropyl)-l-leucinamide |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-secretase 1 | Homo sapiens (human) | IC50 (µMol) | 0.0039 | 0.0006 | 1.6194 | 10.0000 | AID1192278; AID241188; AID264166; AID314585; AID317231; AID614067; AID640217 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (16)
Molecular Functions (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| amyloid-beta binding | Beta-secretase 1 | Homo sapiens (human) |
| endopeptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| aspartic-type endopeptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| protein binding | Beta-secretase 1 | Homo sapiens (human) |
| peptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| beta-aspartyl-peptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| enzyme binding | Beta-secretase 1 | Homo sapiens (human) |
| protein serine/threonine kinase binding | Beta-secretase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (20)
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID241188 | Inhibitory activity against beta-secretase 1 (BACE1) | 2005 | Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1 | Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. |
| AID264164 | Inhibition of BACE1 at 2 uM | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres. |
| AID614067 | Inhibition of BACE1 | 2011 | Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17 | Structure-guided design and synthesis of P1' position 1-phenylcycloalkylamine-derived pentapeptidic BACE1 inhibitors. |
| AID243835 | Inhibitory activity against beta-secretase 1 (BACE1) at 0.2 uM | 2005 | Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1 | Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. |
| AID317230 | Inhibition of human recombinant BACE1 at 0.2 uM | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5 | BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety. |
| AID243826 | Inhibitory activity against beta-secretase 1 (BACE1) at 2 uM | 2005 | Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1 | Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. |
| AID264165 | Inhibition of BACE1 at 0.2 uM | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres. |
| AID317229 | Inhibition of human recombinant BACE1 at 2 uM | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5 | BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety. |
| AID317231 | Inhibition of BACE1 | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5 | BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety. |
| AID314585 | Inhibition of human recombinant BACE1 by FRET assay | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5 | Novel non-peptidic and small-sized BACE1 inhibitors. |
| AID640217 | Inhibition of human recombinant BACE1 by FRET assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2 | Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design. |
| AID1192278 | Inhibition of BACE1 (unknown origin) | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | Novel β-amyloid aggregation inhibitors possessing a turn mimic. |
| AID264166 | Inhibition of BACE1 | 2006 | Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9 | Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.39) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||